🚀 VC round data is live in beta, check it out!
Sensorion Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sensorion and similar public comparables like Sol-Gel Technologies, OmniAb, Voyager Therapeutics, Adimmune and more.
Sensorion Overview
About Sensorion
Sensorion SA is a France-based clinical-stage biotech company dedicated to developing therapies to restore, treat, and prevent hearing loss. The company's product is in phase 2a clinical development, SENS-401 (Arazasetron) in Sudden Sensorineural Hearing Loss (SSNHL). SENS-401 is being developed to treat cochlear pathologies. The Company does business in a single operating segment: conducting research and development to discover drugs to treat inner ear disorders with a view to their future marketing. The company's pipeline programs are SENS-401 SSNHL, SENS-401 CIO, GJB2-GT, GJB2-GT, SENS-401 Cochlear, and others.
Founded
2010
HQ
Employees
65
Website
Sectors
Financials (LTM)
EV
$188M
Sensorion Financials
Sensorion reported last 12-month revenue of $11M and negative EBITDA of ($29M).
In the same LTM period, Sensorion generated $11M in gross profit, ($29M) in EBITDA losses, and had net loss of ($32M).
Revenue (LTM)
Sensorion P&L
In the most recent fiscal year, Sensorion reported revenue of $7M and EBITDA of ($34M).
Sensorion expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $11M | XXX | $7M | XXX | XXX | XXX |
| Gross Profit | $11M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($29M) | XXX | ($34M) | XXX | XXX | XXX |
| EBITDA Margin | (254%) | XXX | (510%) | XXX | XXX | XXX |
| EBIT Margin | (254%) | XXX | (529%) | XXX | XXX | XXX |
| Net Profit | ($32M) | XXX | ($34M) | XXX | XXX | XXX |
| Net Margin | (282%) | XXX | (506%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sensorion Stock Performance
Sensorion has current market cap of $242M, and enterprise value of $188M.
Market Cap Evolution
Sensorion's stock price is $0.47.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $188M | $242M | 0.4% | XXX | XXX | XXX | $-0.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSensorion Valuation Multiples
Sensorion trades at 16.6x EV/Revenue multiple, and (6.5x) EV/EBITDA.
EV / Revenue (LTM)
Sensorion Financial Valuation Multiples
As of April 18, 2026, Sensorion has market cap of $242M and EV of $188M.
Equity research analysts estimate Sensorion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sensorion has a P/E ratio of (7.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $242M | XXX | $242M | XXX | XXX | XXX |
| EV (current) | $188M | XXX | $188M | XXX | XXX | XXX |
| EV/Revenue | 16.6x | XXX | 28.0x | XXX | XXX | XXX |
| EV/EBITDA | (6.5x) | XXX | (5.5x) | XXX | XXX | XXX |
| EV/EBIT | (6.5x) | XXX | (5.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 16.6x | XXX | — | XXX | XXX | XXX |
| P/E | (7.6x) | XXX | (7.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sensorion Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sensorion Margins & Growth Rates
Sensorion's revenue in the last 12 month grew by 54%.
Sensorion's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.6M for the same period.
Sensorion Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 54% | XXX | 233% | XXX | XXX | XXX |
| EBITDA Margin | (254%) | XXX | (510%) | XXX | XXX | XXX |
| EBITDA Growth | (8%) | XXX | (63%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 55% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 314% | XXX | 508% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 541% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sensorion Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sensorion | XXX | XXX | XXX | XXX | XXX | XXX |
| Sol-Gel Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| OmniAb | XXX | XXX | XXX | XXX | XXX | XXX |
| Voyager Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Adimmune | XXX | XXX | XXX | XXX | XXX | XXX |
| Nkarta | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sensorion M&A Activity
Sensorion acquired XXX companies to date.
Last acquisition by Sensorion was on XXXXXXXX, XXXXX. Sensorion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sensorion
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSensorion Investment Activity
Sensorion invested in XXX companies to date.
Sensorion made its latest investment on XXXXXXXX, XXXXX. Sensorion invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sensorion
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sensorion
| When was Sensorion founded? | Sensorion was founded in 2010. |
| Where is Sensorion headquartered? | Sensorion is headquartered in France. |
| How many employees does Sensorion have? | As of today, Sensorion has over 65 employees. |
| Is Sensorion publicly listed? | Yes, Sensorion is a public company listed on Euronext Paris. |
| What is the stock symbol of Sensorion? | Sensorion trades under ALSEN ticker. |
| When did Sensorion go public? | Sensorion went public in 2015. |
| Who are competitors of Sensorion? | Sensorion main competitors are Sol-Gel Technologies, OmniAb, Voyager Therapeutics, Adimmune. |
| What is the current market cap of Sensorion? | Sensorion's current market cap is $242M. |
| What is the current revenue of Sensorion? | Sensorion's last 12 months revenue is $11M. |
| What is the current revenue growth of Sensorion? | Sensorion revenue growth (NTM/LTM) is 54%. |
| What is the current EV/Revenue multiple of Sensorion? | Current revenue multiple of Sensorion is 16.6x. |
| Is Sensorion profitable? | No, Sensorion is not profitable. |
| What is the current EBITDA of Sensorion? | Sensorion has negative EBITDA and is not profitable. |
| What is Sensorion's EBITDA margin? | Sensorion's last 12 months EBITDA margin is (254%). |
| What is the current EV/EBITDA multiple of Sensorion? | Current EBITDA multiple of Sensorion is (6.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.